Michael Davidson/LinkedIn
Nov 23, 2025, 14:48
Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction
Michael Davidson, CEO of NewAmsterdam Pharma, posted on LinkedIn:
”Today’s standard lipid-lowering therapies focus almost exclusively on LDL-C reduction. Yet across large-scale studies, only 20–35% of patients taking them are meeting their risk-based LDL-C goals, highlighting the need for additional therapies.
Additionally, to maximize cardiovascular risk reduction, we need to address additional factors like lipoprotein(a), small LDL particles, and ApoB.
Learn how we can broaden the approach to reducing cardiovascular risk.”
Read more here.
Stay updated wth Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal